{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:47:44Z","timestamp":1782892064994,"version":"3.54.5"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Tislelizumab, an immune checkpoint inhibitor, is widely used in the treatment of various malignancies; however, its immune-related adverse events(irAEs) require careful attention. Here, we report a case of a patient with recurrent urothelial carcinoma who developed myositis and myasthenia-like manifestations after receiving tislelizumab, despite negative myasthenia-associated antibodies. The patient\u2019s symptoms gradually alleviated following treatment with corticosteroids and intravenous immunoglobulin. To our knowledge, antibody-negative myasthenia gravis associated with tislelizumab has been scarcely documented. This case highlights that in patients receiving tislelizumab, early pharmacological intervention should be considered when typical myasthenia-like manifestations occur, even in the absence of antibody positivity, emphasizing the importance of prompt recognition and timely treatment.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1854332","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:56:56Z","timestamp":1782885416000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tislelizumab-induced myositis antibody-negative myasthenia gravis in patients with urothelial carcinoma: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Yi","family":"Bu","sequence":"first","affiliation":[{"name":"Department of Neurology, affiliated Hospital of Chengde Medical University","place":["Chengde, Hebei, China"]},{"name":"Hebei Key Laboratory of Panvascular Diseases","place":["Chengde, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, affiliated Hospital of Chengde Medical University","place":["Chengde, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangmei","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Neurology, affiliated Hospital of Chengde Medical University","place":["Chengde, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, affiliated Hospital of Chengde Medical University","place":["Chengde, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, affiliated Hospital of Chengde Medical University","place":["Chengde, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2022.01.001","article-title":"Immune-related adverse events in various organs caused by immune checkpoint inhibitors","volume":"71","author":"Okiyama","year":"2022","journal-title":"Allergol Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114621","article-title":"Reinstating immunogenicity using bispecific anti-checkpoint\/agent inhibitors","volume":"162","author":"Mortezaee","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2025-335998","article-title":"Neurological immune-related adverse events with checkpoint inhibitor therapy: Challenges for the neurologist","volume":"96","author":"Willis","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-01001-6","article-title":"Peripheral nervous system immune-related adverse events due to checkpoint inhibition","volume":"20","author":"O'Hare","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1053370","article-title":"Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100317","article-title":"How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors","volume":"6","author":"Jordan","year":"2021","journal-title":"ESMO Open"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1496427","article-title":"Case report: A severe myositis mimicking bulbar palsy after administration of immune checkpoint inhibitors","volume":"16","author":"Rochigneux","year":"2025","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200177","article-title":"Immune checkpoint inhibition-related myasthenia-myositis-myocarditis responsive to complement blockade","volume":"11","author":"Nelke","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.18295\/2075-0528.2796","article-title":"Cardiac markers in the early diagnosis and management of patients with acute coronary syndrome","volume":"9","author":"Al-Hadi","year":"2009","journal-title":"Sultan Qaboos Univ Med J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/liv.15099","article-title":"Gamma-glutamyl transferase (gamma-Gt) - an old dog with new tricks","volume":"42","author":"Brennan","year":"2022","journal-title":"Liver Int"},{"key":"B11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3892\/mi.2024.210","article-title":"Myositis\/myasthenia gravis caused by immune checkpoint inhibition: A report of two cases and a brief review of the literature","volume":"5","author":"Elavia","year":"2025","journal-title":"Med Int (Lond)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101192","article-title":"Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: A multicentric, retrospective cohort study","volume":"50","author":"Plomp","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1372861","article-title":"Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: A single center experience and systematic review","volume":"15","author":"Qin","year":"2024","journal-title":"Front Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1854332\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:56:57Z","timestamp":1782885417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1854332\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":13,"alternative-id":["10.3389\/fimmu.2026.1854332"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1854332","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1854332"}}